SOLTI strengthens its business development plan by adding Ramón Mel to its Management Team
- NOTA DE PRENSA
This appointment is part of the Group’s strategic plan for the period 2024-2027, defined after the designation of the current Executive Board with Dr. Mafalda Oliveira as President
Ramón Mel will join SOLTI’s Management Team to drive the Group’s expansion in the coming years, in the role of Deputy CEO
SOLTI, a clinical research group in oncology, is a reference in the sector with an accumulated experience of more than 80 clinical trials, mainly in breast cancer
Barcelona, March 21, 2024.- SOLTI, a leading group in clinical research in breast cancer and other tumors in Spain, strengthens its consolidation and expansion strategy with the addition of Ramón Mel to its Management Team, effective April 1, in the position of Deputy CEO, with the aim of accelerating the Group’s national and international development plans and reinforcing its strategic areas of action.
Mel will lead the Business Development Plan that will consolidate SOLTI’s leadership in cancer research and knowledge. To this end, he will work closely with SOLTI’s current CEO, Dr. Ramon Estiarte, and with the Group’s Executive Board, chaired by Dr. Mafalda Oliveira, in a process that will ensure the achievement of the organization’s strategic objectives linked to the expansion into new areas of interest. Likewise, this incorporation is part of a transition process linked to the replacement of our current CEO during the next year 2025.
Ramón Mel has a track record of more than 20 years in the pharmaceutical industry, where he has held positions of increasing strategic responsibility in companies such as GSK, Roche and AstraZeneca. In addition to his career in Spain, Mel has a solid international experience that has led him to lead key projects and activities in his previous companies: his career is characterized by his involvement in strategic transformation projects, the impact on results and the creation of high-performance teams that have allowed the companies in which he has worked to become an international reference in their field. Ramón comes to us from AstraZeneca, where he headed the company’s oncology unit in Spain and was a member of its Spanish and European steering committees. He also holds the position of Secretary of the Galician Medical Association (ASOMEGA), to which he was recently re-elected following the organization’s elections.
Dr. Mafalda Oliveira, President of SOLTI, emphasized that “since its foundation in 1995, SOLTI’s mission has been to seek a paradigm shift in the approach and treatment of cancer. To this end, we believe it is essential to constantly integrate talent, either through a firm commitment to new generations of researchers or by promoting the strategic expansion of the Group at a global level in order to meet the new challenges in the field of oncology. It is in this latter aspect that the incorporation of Ramón Mel provides an additional boost”.
For his part, the current CEO of the Group, Dr. Ramon Estiarte, said that “with the effort and contribution of the entire SOLTI team, in recent years we have positioned the Group as a leader in clinical and translational research in cancer thanks to the design and execution of innovative clinical trials based on the molecular biology of tumors, with wide recognition at national and international levels. We will continue to work together in this direction, now with the addition of a new member who will bring a fresh perspective in line with SOLTI’s values and strategic interests”.
Dr. Mafalda Oliveira adds that “from the SOLTI Executive Board, we greatly appreciate the work of Ramon Estiarte in consolidating the current position of the Group and we are sure that the incorporation of Ramón Mel will bring an enriching vision and experience within the framework of the objectives of our Strategic Plan 2024-2027”.
SOLTI: Over 25 years of Breast Cancer Research
SOLTI is a reference group in clinical cancer research in Spain. With a consolidated trajectory of more than 25 years, its main activity is focused on the design and execution of translational clinical studies within the academic field. Its interest has been focused on breast cancer, but it opens its scope to other tumors. SOLTI has an accumulated experience of 80 clinical trials and more than 30 in progress, and is made up of 480 researchers in a network of 100 centers in Spain, Portugal and Ireland, coordinated by a central office with a team of more than 60 people.
SOLTI is part of the Spanish Society of Medical Oncology (SEOM) and is a non-profit association that, in addition to its scientific activity, has a medical and patient education program with several annual initiatives. The Group’s mission is innovative research to improve the prognosis and well-being of patients with breast cancer and other tumors.
